Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8894360 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL938866 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8895726 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8849361 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8812077 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8893734 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8894556 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8896962 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8894824 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT | |
| SCHEMBL8893917 | 1.00 | DGKA (0.55) | DGKALMNATSHRPAMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11746119-B2 | Cardiopathy-reducing phosphodiester lipids | SIGNPATH PHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11643424-B2 | Cardiopathy-reducing phosphodiester lipids | SIGNPATH PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220056057-A1 | Novel Lipids | SIGNPATH PHARMA INC. | 2022-02-24 | — | — | US | disclosed |
| US-20210198294-A1 | Novel Lipids | SIGNPATH PHARMA INC. | 2021-07-01 | — | — | US | disclosed |
| EP-3813820-A1 | NOVEL LIPIDS | Signpath Pharma, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10975111-B2 | Cardiopathy-reducing phosphodiester lipids | SIGNPATH PHARMA, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-5670563-A | ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND | CIBA-SPECIALTY CHEMICALS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056057-A1 | Novel Lipids | LCAT, LIPC, CETP | DGKA 195/4885LMNA 1179/4885TSHR 4029/4885 |
| US-11746119-B2 | Cardiopathy-reducing phosphodiester lipids | TNNT2, TNNI3, FABP3 | DGKA 70/4885LMNA 385/4885TSHR 3890/4885 |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | DGKA 897/4885LMNA 262/4885TSHR 1085/4885 |
| US-20210198294-A1 | Novel Lipids | LCAT, LIPC, CETP | DGKA 195/4885LMNA 1182/4885TSHR 4029/4885 |
| US-11643424-B2 | Cardiopathy-reducing phosphodiester lipids | TNNT2, TNNI3, FABP3 | DGKA 70/4885LMNA 385/4885TSHR 3890/4885 |
| US-10975111-B2 | Cardiopathy-reducing phosphodiester lipids | TNNT2, TNNI3, FABP3 | DGKA 70/4885LMNA 385/4885TSHR 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.